Sangamo Therapeutics Analyst Ratings
Sangamo Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 362.96% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/11/2023 | 825.93% | Wedbush | $16 → $10 | Maintains | Outperform |
| 08/10/2023 | 270.37% | Wells Fargo | $5 → $4 | Maintains | Overweight |
| 08/09/2023 | 733.33% | Barclays | $11 → $9 | Maintains | Overweight |
| 08/09/2023 | 455.56% | RBC Capital | $8 → $6 | Maintains | Outperform |
| 05/10/2023 | 640.74% | Truist Securities | $16 → $8 | Maintains | Buy |
| 05/01/2023 | 362.96% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 04/28/2023 | 38.89% | B of A Securities | $5 → $1.5 | Downgrades | Neutral → Underperform |
| 03/03/2023 | 1288.89% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 02/27/2023 | 1381.48% | Wedbush | → $16 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 1103.7% | RBC Capital | $22 → $13 | Maintains | Outperform |
| 01/04/2023 | 1288.89% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 11/07/2022 | 1751.85% | Wells Fargo | $22 → $20 | Maintains | Overweight |
| 06/13/2022 | 362.96% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 1659.26% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 1937.04% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 1381.48% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 2214.81% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 1751.85% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 1937.04% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 1196.3% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 918.52% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 918.52% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月14日 | 362.96% | HC Wainwright公司 | →$5 | 重申 | 购买→购买 |
| 2023年08月11日 | 825.93% | 韦德布什 | $16→$10 | 维护 | 跑赢大盘 |
| 2023年08月10日 | 270.37% | 富国银行 | $5→$4 | 维护 | 超重 |
| 08/09/2023 | 733.33% | 巴克莱 | $11→$9 | 维护 | 超重 |
| 08/09/2023 | 455.56% | 加拿大皇家银行资本 | $8→$6 | 维护 | 跑赢大盘 |
| 2023年05月10日 | 640.74% | Truist证券 | $16→$8 | 维护 | 买 |
| 05/01/2023 | 362.96% | HC Wainwright公司 | $15→$5 | 维护 | 买 |
| 04/28/2023 | 38.89% | B of A证券 | $5→$1.5 | 评级下调 | 中性→表现不佳 |
| 03/03/2023 | 1288.89% | HC Wainwright公司 | $25→$15 | 维护 | 买 |
| 02/27/2023 | 1381.48% | 韦德布什 | →$16 | 升级 | 中性→表现优异 |
| 02/23/2023 | 1103.7% | 加拿大皇家银行资本 | $22→$13 | 维护 | 跑赢大盘 |
| 01/04/2023 | 1288.89% | 富国银行 | $20→$15 | 维护 | 超重 |
| 11/07/2022 | 1751.85% | 富国银行 | $22→$20 | 维护 | 超重 |
| 2022/06/13 | 362.96% | 韦德布什 | →$5 | 假设 | →中性 |
| 04/05/2022 | 1659.26% | Truist证券 | $23→$19 | 维护 | 买 |
| 05/04/2021 | 1937.04% | 加拿大皇家银行资本 | →$22 | 开始承保 | →跑赢大盘 |
| 01/06/2021 | 1381.48% | Stifel | →$16 | 开始承保 | →保留 |
| 12/16/2020 | 2214.81% | HC Wainwright公司 | →$25 | 假设 | →购买 |
| 09/08/2020 | 1751.85% | B of A证券 | →$20 | 恢复 | →购买 |
| 07/07/2020 | 1937.04% | SunTrust Robinson Humphrey | →$22 | 开始承保 | →购买 |
| 06/22/2020 | 1196.3% | HC Wainwright公司 | $16→$14 | 维护 | 买 |
| 2018年11月14日 | 918.52% | 摩根大通 | $35→$11 | 维护 | 中性 |
| 2018年11月14日 | 918.52% | 摩根大通 | $35→$11 | 评级下调 | 超重→中性 |
| 2018/09/11 | - | 古根海姆 | 评级下调 | 购买→中性 |
What is the target price for Sangamo Therapeutics (SGMO)?
Sangamo治疗公司(SGMO)的目标价格是多少？
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by HC Wainwright & Co. on August 14, 2023. The analyst firm set a price target for $5.00 expecting SGMO to rise to within 12 months (a possible 362.96% upside). 13 analyst firms have reported ratings in the last year.
桑加莫治疗公司(纳斯达克代码：SGMO)的最新目标价是由HC Wainwright&Co.于2023年8月14日报道的。这家分析公司将目标价定为5美元，预计新交所股价将在12个月内上涨(涨幅可能为362.96%)。过去一年，有13家分析公司公布了评级。
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
Sangamo治疗公司(SGMO)的最新分析师评级是多少？
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by HC Wainwright & Co., and Sangamo Therapeutics reiterated their buy rating.
桑加莫治疗公司(纳斯达克代码：SGMO)的最新分析师评级由HC Wainwright&Co.提供，Sangamo治疗公司重申其买入评级。
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Sangamo治疗公司(SGMO)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Sangamo治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Sangamo治疗公司的上一次评级是在2023年8月14日提交的，所以你应该预计下一次评级将在2024年8月14日左右的某个时候提供。
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
分析师对Sangamo Treeutics(SGMO)的评级正确吗？
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a reiterated with a price target of $0.00 to $5.00. The current price Sangamo Therapeutics (SGMO) is trading at is $1.08, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Sangamo治疗(SGMO)评级被重申，目标价在0.00美元至5.00美元之间。Sangamo治疗公司(SGMO)目前的交易价格为1.08美元，在分析师的预测范围内。